Site Search
Professionals 433 results
Capabilities 76 results
Practice Area
Our structured finance group is widely recognized as a leader, encompassing Esoteric Finance, Residential Asset Finance and Securitization, and CLOs/Fund Finance. Positioned prominently at the forefront of the industry, our team boasts extensive experience across a broad spectrum of assets, with a particular focus on bespoke structures and emerging and/or “esoteric” assets, including residential and commercial PACE, RMBS, and CMBS; aircraft, vessel, and railcar finance; FinTech and marketplace lending; CLOs; specialty finance; consumer and business lending; energy structured finance (including solar finance and reserve-based finance); derivatives and structured products; lease and operating asset finance; trade receivables; litigation settlement financing; and life settlements.
Practice Area
Keeping a deal moving forward can be challenging. Our 100+ Finance attorneys help clients maintain momentum with a commitment to understanding the challenges, risks, and opportunities they face. Our team has developed great insights through the representation of financial institutions and corporate enterprises of all types and sizes in the finance industry. We have a well-rounded finance practice, with dedicated teams that advise banks, credit funds, alternative capital providers, sponsors, and corporations on a wide range of transactions including debt finance (leveraged, asset-based, and reserve-based lending), fund finance, structured finance, derivatives and structured products, project finance, and transportation finance.
Practice Area
We advise clients that originate, manage, and invest in broadly syndicated and middle-market corporate loans with their fund formation and capital markets fund-financing activities. Our experience includes structure and formation of CLOs, registered funds, hedge funds, listed funds, private credit funds, managed accounts, synthetic funds, SBICs, and onshore and offshore special purpose investment vehicles. Our experience spans the complete spectrum of services, including warehouse, leverage, and subscription facilities and ongoing portfolio support. Our Capital Markets Practice has extensive experience in debt and equity offerings, spin-offs, split-offs, and carve-outs, as well as securities compliance and corporate governance.
Experience 94 results
Experience
|October 21, 2024
Investcorp AI Acquisition Corp. Announces Entry into Business Combination
Experience
|October 15, 2024
Experience
|September 27, 2024
Winston Represents KeHE Distributors, LLC in a $250.0 Million Senior Secured Notes Tack-On Offering
Insights & News 1,504 results
In the Media
|November 19, 2024
|1 Min Read
Winston & Strawn’s Miami Office Growth Featured in Law360 Office Spotlight
Winston & Strawn’s Miami office growth and upcoming expansion to two floors in the Southeast Financial Center was featured in a Law360 Office Spotlight article. In 2025, attorneys and staff will move from the 24th floor to the permanent space on the 17th and 18th floors, totaling 45,134 square feet. The new office will be connected by an internal staircase and can accommodate double the number of employees than the current space. The office will feature a conference center and unobstructed views of Biscayne Bay and the Port of Miami from the reception area.
Client Alert
|November 14, 2024
|7 Min Read
SEC Division of Examinations 2025 Priorities
On October 21, 2024, the U.S. Securities and Exchange Commission’s (the SEC) Division of Examinations (the Division) announced its annual list of examination priorities for 2025 (the Priorities), which are developed in consultation with various internal SEC divisions and offices. The priorities reflect practices, products, and services that the Division believes present heightened risks to investors or the integrity of the U.S. capital markets. The Priorities are not an exhaustive list of issues the Division intends to target in examinations. The Division’s examinations are also likely to address emerging risks, products, market events, and other investor concerns as they arise. In this alert, you will find a summary of the priorities for the SEC in examining registered investment advisers, registered investment companies, broker-dealers, and other market participants in 2025.
Competition Corner
|November 14, 2024
|8 Min Read
A Second Trump Presidency: How Will It Impact Antitrust Merger Review?
Last week, Donald Trump was elected to serve as the 47th president of the United States. President Trump’s election raises questions about the future of antitrust policy and enforcement, particularly following the major policy shifts and increased scrutiny of mergers and acquisitions under the Biden administration.
Other Results 43 results
Site Content
ESG in finance can refer to, among other things, financing tools such as Green, Social, and Sustainability Bonds and similar ESG-related debt instruments, as well as the separate discipline of ESG Investing. ESG stands for Environmental, Social, and Governance. Investors are increasingly applying these non-financial factors as part of their analysis to identify ESG-related risks and opportunities in particular investments. ESG metrics have not historically been included in financial reporting, though companies are increasingly making disclosures in their annual report or in a standalone sustainability report, and regulatory requirements for such disclosures, including from the SEC, are expanding.
Site Content
Definitions of big data may differ within the computing or business world. In general, the term refers to structured and unstructured data that is extremely large in volume and/or complex—and due to these characteristics, it is difficult to manage with standard data processing or storage. The phrase “big data” may also refer to the processing techniques that an organization employs to manage the huge, complex, or time-sensitive sets of information it receives.
Law Glossary
How Does an Applicant Establish Biosimilarity?
An applicant typically demonstrates biosimilarity based on non-clinical analyses that focus on the structure and functional differences between the biosimilar and reference product.